Jw Life Science Corp Cash Flow-to-Debt Ratio
Jw Life Science Corp cash flow-to-debt ratio. Jw Life Science Corp (234080) has a Cash Flow-to-Debt Ratio of 0.22x as of June 2026, meaning its operating cash flow of ₩17.43 Billion could theoretically repay 0% of its total liabilities (₩79.02 Billion) in one year. Check Jw Life Science Corp total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jw Life Science Corp (2015–2025)
Cash flow-to-debt ratio of Jw Life Science Corp from 2015 to 2025. Historical debt coverage capacity for Jw Life Science Corp across 11 annual periods. Check how high is Jw Life Science Corp's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Jw Life Science Corp Cash Flow-to-Debt Ratio by Year (2015–2025)
Jw Life Science Corp cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Jw Life Science Corp. For the full cash flow conversion analysis, see Jw Life Science Corp (234080) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.42x | ₩40.54 Billion | ₩97.63 Billion | ▲ +2.3% |
| 2024 | 0.41x | ₩50.69 Billion | ₩124.88 Billion | ▲ +4.2% |
| 2023 | 0.39x | ₩37.57 Billion | ₩96.44 Billion | ▲ +210.5% |
| 2022 | 0.13x | ₩14.13 Billion | ₩112.61 Billion | ▼ -63.4% |
| 2021 | 0.34x | ₩30.17 Billion | ₩87.97 Billion | ▼ -36.9% |
| 2020 | 0.54x | ₩46.75 Billion | ₩85.98 Billion | ▲ +76.5% |
| 2019 | 0.31x | ₩24.28 Billion | ₩78.79 Billion | ▼ -21.9% |
| 2018 | 0.39x | ₩36.13 Billion | ₩91.60 Billion | ▲ +72.5% |
| 2017 | 0.23x | ₩22.05 Billion | ₩96.43 Billion | ▲ +45.0% |
| 2016 | 0.16x | ₩16.08 Billion | ₩101.94 Billion | ▼ -40.9% |
| 2015 | 0.27x | ₩25.90 Billion | ₩97.05 Billion | — |